In the trial, 948 patients were randomized to receive a 1500mg fixed dose of IMFINZI plus FLOT chemotherapy or placebo plus FLOT chemotherapy every four weeks for two cycles prior to surgery.

The mid-stage Study 22 trial found that a single priming dose with AZ’s CTLA4 inhibitor tremelimumab, followed by PD-L1 inhibitor Imfinzi (durvalumab) given every four weeks, performed the best ...

AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited ... Legend reported no dose-limiting toxicities up to the highest dose of LB2102 tested and observed better tumor ...

Imfinzi and tremelimumab will also have to contend with Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab), low-dose CTLA4 inhibitor Yervoy (ipilimumab) and chemotherapy ...

Corvus' soquelitinib shows promise in oncology & autoimmune fields, with Phase 3 PTCL data as a key catalyst. Click here to ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab (Imfinzi ... followed by a 1500-mg dose of durvalumab or placebo ...

Patients received durvalumab at a dose of 1,500 mg or placebo every 4 weeks plus FLOT for 4 cycles (2 cycles each of neoadjuvant and adjuvant therapy), followed by durvalumab or placebo every 4 ...

A second phase 3 trial, MATTERHORN (NCT04592913), met its end point of event-free survival; the study evaluated adding durvalumab (Imfinzi ... possible uses of low-dose endocrine therapy to ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Investigators randomly assigned 948 patients in a 1:1 ratio to receive Imfinzi at a fixed dose of 1500 mg plus FLOT chemotherapy (n = 474) or placebo plus FLOT (n = 474) administered in two cycles ...

WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination ...